12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abraxane nab-paclitaxel: Phase III data

The open-label, international Phase III MPACT trial in 861 treatment-naïve patients with metastatic pancreatic cancer showed that 125 mg/m 2 Abraxane plus gemcitabine met the primary endpoint of OS vs. gemcitabine alone. Celgene said the data have been submitted for presentation at the American Society of Clinical...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >